Important notice

Interruption of online services

We will be carrying a maintenance of our online services from 22:00 p.m. on April 4 to 8:00 a.m. on April 5. Our online services will be unavailable, including the following: registration for and deregistration from the prescription drug insurance, replacement of a Health Insurance Card, organ donation, and advance medical directives. Thank you for your understanding.

Gouvernement du Québec
Régie de l’assurance maladie

Notice of alternative medication authorization, July 11, 2022

Legal publication
Updated on

 16 August 2022

This notice was published on August 16, 2022.

Tocilizumab (162 mg/0.9 ml (4 ml)), Tocilizumab (162 mg/0.9 ml (10 ml)) et Tocilizumab (162 mg/0.9 ml (20 ml)) remplace:

  • Actemra (162 mg/0.9 ml) – S.C. Inj. Sol (syr)
  • Actemra (162 mg/0.9 ml) – S.C. Inj. Sol (pen)
Download (.pdf)
 63.73 KB
Related topics